From: "Dr. Henry Jarecki" To: 'Jeffrey Epstein' <jeevacationggmail.com> Subject: FW: DeCode Date: Wed, 12 Aug 2009 23:32:26 +0000 A great idea gone bad but maybe still salvageable. And what's happened to you otherwise? From: Kozikowski, Alan [mailto Sent: Wednesday, August 12, 09 14:12 To: Dr. Henry Jarecki Subject: FW: DeCode Henry.... Opps... not good below. Hope you are good. Alan From: Yuen, Po-wai Sent: Wednesday, August 12, 2009 11:42 AM To: Kozikowski, Alan Subject: DeCode Icelandic biotech deCODE Genetics may become another casualty of tough economic times. The company announced today, (August 11) that it has only $3.8 million dollars left in its coffers •• enough to fund operations "into the latter half of the third quarter," which in Iceland runs through September. In a conference call this morning, the company said it was restructuring its business, dropping its medicinal chemistry and structural biology operations, and instead focusing on providing commercial and consumer genetics services. "We are making good progress in recasting deCODE as a leading DNA-based diagnostics company," Kari Stefansson, the company's CEO, said on the call. Going forward, said Stefansson, the three main elements of its business will be the company's consumer genome-based diagnostics business decodeME, as well as scientific services (providing genotyping, sequencing, and data management) and out-licensing for genetic markers. A $10 million deal struck in April, for example, granted genomics company Cetera a license to use deCODE-discovered markers for cardiovascular and metabolic disease risk. More such deals, or an alternative infusion of funds, will be needed to keep the company in business, however. EFTA00773632